This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Kazuki Ohta, MD; Yukio Hirata, MD; Masayoshi Shichiri, MD; Masahiko Ichioka, MD; Tbshiro Kubota, MD; Fumiaki Marumo, MD
Tokyo (Japan) Medical and Dental University

JAMA. 1991;265(11):1391-1392.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor. —

Endothelin-1 (ET-1) is a 21-residue vasoconstrictor-pressor peptide originally isolated and sequenced from porcine aortic endothelial cells.¹ We have recently demonstrated the production of ET-like immunoreactivity (LI) by renal tubular cells and the presence of ET-LI in human urine.² We have further shown that urinary ET-LI excretion levels remarkably increased in patients with renal disease, which originates, at least in part, from the affected renal tubules.³ To elucidate whether urinary ET-LI is a marker for tubular injury, we measured urinary excretion levels of ET-LI in patients treated with cisplatin, a chemotherapeutic agent that often causes renal tubular damage.

Study. —

The present group consisted of six patients (three men and three women aged 50.0 ±6.4 years, mean± SEM) with cancers of various origins: adenocarcinoma of lung (two patients), ovarian papillary cystadenocarcinoma (two), lung metastasis of mandibular carcinoma (one), and mediastinal germ cell tumor (one). . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?